Tramadol, buy tramadol, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, weight loss, hair loss, hair growth, baldness, alopecia, Rx Online, pharmaceuticals, DHEA, Lutein, Prescription, Prescription drug, prescription medications, immune system.

DreamPharm Products:

Eur J Med Res. 2002 Aug 30;7(8):359-67.
Induction of antibodies to viscotoxins A1, A2, A3, and B in tumour patients during therapy with an aqueous mistletoe extract.

Klein R, Classen K, Fischer S, Errenst M, Scheffler A, Stein GM, Scheer R, von Laue HB.

Department of Internal Medicine II, University of Tubingen, Germany. reinhild.kleied.uni-tuebingen.de

Mistletoe extracts exert immunomodulatory properties on immunocompetent cells of the innate as well as the specific immune system. These effects have been mainly ascribed to mistletoe lectin 1 (ML-1) present in most of the extracts. However, it became evident that also other components of these extracts may induce immunological reactions, and especially viscotoxins (VT) may be of relevance. Aim of the study was, therefore, to evaluate whether VT like ML-1 could activate B-cells and lead to the production of VT-specific antibodies. Sera from 26 patients with different tumours who were treated with the mistletoe extract ABNOBAviscum Mali (AM) 4 for at least 18 weeks were analysed before therapy and after 3, 6, 9, 12, and 18 weeks. Sera were tested by ELISA against the four viscotoxins A1, A2, A3, B, as well as against ML-1. Within the observation period twenty-four (92%) of the 26 patients developed antibodies to at least one of the four VT and 25 (96%) to ML-1. In most instances, anti-VT antibodies appeared after 6-9 weeks of treatment. The antibodies were predominantly of the IgG type belonging preferentially to the IgG1 and IgG3 subclass. IgE antibodies were found only to VT-B and to ML-1. There was no relation between the development of antibodies to VT and ML-1, and also cross-reactivity could be excluded with high probability. These data indicate that not only ML-1 but also VT induce immunological responses in patients treated with mistletoe extracts. Whether there is any relationship to the postulated anti-tumour effect of mistletoe extracts has, however, still to be evaluated.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12204844&dopt=Abstract

Hua Xi Yi Ke Da Xue Xue Bao. 1999 Mar;30(1):34-6.
[An investigation of immunoprotecting mechanism of macroencapsulated pancreatic islet xenograft]

[Article in Chinese]

Yang H, Zhang P, Zhang C.

Department of Endocrinology, First Affiliated Hospital, WCUMS, Chengdu 610041.

Macroencapsulated islet xenografts in agarose are able to prevent rejection. This study was conducted to shed light on the immunoprotecting mechanism of macroencapsulated islet xenografts in agarose. There were four groups (n = 5 in each group): (1) macroencapsulated islet xenografts in agarose; (2) nonencapsulated islet xenografts; (3) agarose macroeencapsule without islet; (4) syngenic pancreatic islets. Mixed lymphocyte islet culture (MLIC) was used in the experiment. The results showed that stimulating index (SI) of MLIC and IL-2 level in the macroencapsulated islet xenografts in agarose group were similar to those of syngenic pancreatic islets group. The SI and IL-2 levels of nonencapsulated islet xenograft group were significant higher than those in macroencapsulated islet xenografts in agarose group and syngenic pancreatic islets group. These indicate that macroencapsulation is capable of reducing the immunogenicity of islet xenograft, and it is presumable that macroencapsulated islet xenografts in agarose be not recognized by the recipient's immune system because of being separated by the selectively permeable membrane made with agarose.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12205917&dopt=Abstract

Life Sci Space Res. 1971;9:1-9.
Immune states in long-term space flights.

Ginsberg HS.

Department of Microbiology, School of Medicine, University of Pennsylvania, Philadelphia, Penn., USA.

Maintenance of health, as contrasted to illness induced by infectious agents, reflects a tenuous balance between the host's resistance and the number and genetic characteristics of the infectious organisms present. Nature has evolved both nonspecific defense mechanisms and specific immune systems to protect the body against invasion by exogenous organisms or the numerous agents which may reside dormant within the host. Long-term space flights with their accompanying prolonged weightlessness, unaccustomed environmental factors, emotional disturbances, and unforeseen influences may alter the host's natural or specific immune states. The non-specific and specific host defenses will be discussed, and the particular effects which their alteration might have on provocation of latent viral infections will be considered. Viruses which classically may be induced to cause recurrent infections such as herpes simplex and herpes zoster will be described, but in addition the effect that altered host defenses might have on slow virus infections such as kuru and virus-induced malignancies will be emphasized.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12206176&dopt=Abstract

Eur J Immunol. 2002 Sep;32(9):2427-36.
IgVH gene analysis suggests that peritoneal B cells do not contribute to the gut immune system in man.

Boursier L, Farstad IN, Mellembakken JR, Brandtzaeg P, Spencer J.

Guy's, King's and St Thomas' Medical School, Department of Histopathology, St Thomas' Campus, London, GB.

The contribution of peritoneal B cells to the intestinal lamina propria plasma cell population is well documented in mice, but unknown in humans. We have analyzed immunoglobulin (Ig) genes of human peritoneal B cells, because such genes show distinctive characteristics in mucosal B cells, particularly highly mutated variable regions. Here, we report the characteristics of variable region genes used by IgM, IgA and IgG in peritoneal cells. We focused on the properties of IgV(H)4-34 to allow comparisons of like-with-like between different isotypes and cells from different immune compartments. We observed that the IgM genes were mostly unmutated, and that the mutated subset had less mutations than would be expected in a mucosal B cell population. Likewise, the IgV(H)4-34 genes used by IgA and IgG from peritoneal B cells had significantly lower numbers of mutations than observed in the mucosal counterparts. Other trends observed, while not reaching statistical significance, followed the trend of peripheral B cells. The peritoneal B cell population had more IgA1 than IgA2 sequences, and there was no dominance of J(H)4 in the IgA from peritoneum or spleen, in contrast to the mucosal sequences. Overall, this study suggested that human peritoneal B cell are either peripheral or mixed in origin; they are unlikely to represent an inductive compartment for the mucosal B cell system.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12207327&dopt=Abstract

Br J Dermatol. 2002 Sep;147(3):433-41.
Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi.

Andreani V, Richard MA, Blaise D, Gouvernet J, Grob JJ.

Service de Dermatologie et LIMP (Laboratoire d'Investigation des Maladies de la Peau), Hopital Sainte Marguerite, 270 Bd de Sainte Marguerite, Universite de la Mediterranee, 13009 Marseille, France.

BACKGROUND: Non-melanoma skin carcinoma is more common in transplant recipients, probably because of immunosuppression. An increased risk of developing melanoma could be a late effect of transplantation. The number of naevi, which is a risk marker for melanoma, is increased in renal transplant recipients of all ages and may be related to immunosuppression. The risk of melanoma has been suspected to be particularly high after bone marrow transplantation. Cutaneous graft-versus-host disease (GVHD) might be an interesting model for the study of interactions between naevi and the immune system. OBJECTIVE: To assess whether aBMT exposes an individual to a particularly high risk of melanoma, using naevi as a surrogate measure of the risk. To improve our knowledge of the effect of the immune system on naevi, using GVHD as a model. METHODS: We carried out an epidemiological case-control study with two age-, sex- and hair colour-matched controls for each case. The results were analysed with analysis of variance, a general linear model analysis and multivariate analysis. RESULTS: The number of naevi was not significantly increased in aBMT patients, as compared with controls, although there was a significant excess on the palms and legs. In exploratory subgroup case-control comparisons and with the general linear model, patients who were conditioned with a combination of two alkylating drugs at high doses, and patients who had an aBMT before the age of 20 years tended to have a higher count of naevi (P = 0.002 and P = 0.06, respectively). Conversely, there was a trend in favour of a lower count of naevi in patients with diffuse skin lesions of chronic GVHD (P = 0.01). These data were corroborated by multivariate analysis, which showed that conditioning with high-dose chemotherapy, the absence of severe chronic cutaneous GVHD and a young age at transplantation were the main variables that independently predicted an excess of naevi. CONCLUSIONS: This study of aBMT patients confirms that chemotherapy stimulates naevus growth. It also suggests for the first time that diffuse lesions of chronic cutaneous GVHD are associated with a decreased number of naevi. Whether allo-immunity, chronic skin inflammation or the masking of naevi by pigmentation and fibrosis is responsible for the decreased number of naevi requires further investigation. With respect to the long-term risk of melanoma in aBMT recipients, our results support an increased risk particularly when aBMT is performed at a young age, and when conditioning is with high doses of alkylating drugs.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12207581&dopt=Abstract

Beautiful, dense hair is a dream for many people. Hair growth is a sophisticated biological process, which has not yet been understood. A multitude of therapeutic measures, including drugs, surgery, and suppelements have been developed. However, due to the diversity of the problems underlying hair loss, there is no single solution that can address all hair loss cases. Another problem is that most of chemical drugs and hair transplantation surgeries are not free from varying degrees of undesirable side effects on health.

Anecdotally, it shows prositive results and improvement especially for age-related hair thinning and hair loss for a large group of people who take it as suggested. Although personal experiences and anecdotal evidences indicate that it works, we still do not understand the mechanisms of action as to how Hair Million works to help stop hair loss, and promote hair growth. There has been no clinical trials nor placebo controlled statistical analysis on the efficacy of Hair Million on hair loss and hair growth. R & D costs dearly, and no one would afford to research complex herbal ingredients, which are often not patentable at all because they are made by mother nature.

DHEA has been suggested to provide numerous potential benefits. DHEA (or dehydroepiandrosterone) is converted into androgens (male hormones) or estrogens (female hormones) in the cells.

Rx Medications Online|| Celexa Online || Tramadol Online || Paxil Online || Buspar Online || Cialis Online || Flexeril Online || Related Web pages || Herbs and Pharmaceuticals Online ||